Lu-65Homo sapiens (Human)Cancer cell line
Also known as: C-Lu65, C-Lu-65, Lu 65, Lu65, LU65, LU-65, LU-65M
Quick Overview
Lu-65 is a human lung cancer cell line used in cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1392 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Lung[UBERON:UBERON_0002048] |
Donor Information
| Age | 64 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | asian |
Disease Information
| Disease | Lung giant cell carcinoma |
|---|---|
| Lineage | Lung |
| Subtype | Giant Cell Carcinoma of the Lung |
| OncoTree Code | GCLC |
DepMap Information
| Source Type | JCRB |
|---|---|
| Source ID | ACH-000438_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Glu11Gln (c.31G>C) | Unspecified | - | PubMed=32321971 |
| MutationSimple | RB1 | p.Ser82Ter (c.245C>A) | Homozygous | - | from parent cell line Lu-65 |
| MutationSimple | KRAS | p.Gly12Cys (c.34G>T) | Unspecified | - | PubMed=21173094 |
| MutationSimple | EGFR | p.Leu858Arg (c.2573T>G) | Unspecified | In 10% of cells | PubMed=31882684 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Genetic diversity among the present Japanese population: evidence from genotyping of human cell lines established in Japan.
Kasai F., Fukushima M., Miyagi Y., Nakamura Y.
Hum. Cell 37:944-950(2024).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Differential effector engagement by oncogenic KRAS.";
McCormick F.
Cell Rep. 22:1889-1902(2018).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Cancer Sci. 101:1891-1896(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
A gene-alteration profile of human lung cancer cell lines.";
Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
Hum. Mutat. 30:1199-1206(2009).
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.
Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.
Cancer Res. 65:7276-7282(2005).
Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.
Hirohashi S., Inazawa J., Imoto I.
Hum. Mol. Genet. 14:997-1007(2005).
Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer.
Hayashi S., Aozasa K., Kawase I.
Oncogene 22:674-687(2003).
Mutations of the BRAF gene in human cancer.";
Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Nature 417:949-954(2002).
Mutation and expression of the DCC gene in human lung cancer.";
Yokota J.
Neoplasia 2:300-305(2000).
Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.
Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.
Int. J. Oncol. 15:927-934(1999).
Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
Fujishita T., Mizushima Y., Kashii T., Kobayashi M.
Anticancer Res. 18:1537-1542(1998).
Screening the p53 status of human cell lines using a yeast functional assay.
Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Mol. Carcinog. 19:243-253(1997).
Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method.
Kashii T., Mizushima Y., Monno S., Nakagawa K., Kobayashi M.
J. Cancer Res. Clin. Oncol. 120:143-148(1994).
Characterization of two newly established human cell lines from patients with large-cell anaplastic lung carcinoma.
Old L.J.
Cancer 50:1518-1529(1982).